MiNK Therapeutics Inc INKT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)
MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
Trading Information
- Previous Close Price
- $10.22
- Day Range
- $9.53–10.38
- 52-Week Range
- $8.48–16.93
- Bid/Ask
- $8.90 / $10.06
- Shares Outstanding
- 5.10M
- Market Cap
- $48.63M
- Volume/Avg
- 14,705 / 14,298
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 15
Valuation
Metric | INKT |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | INKT |
|---|---|
Quick Ratio | 1.16 |
Current Ratio | 1.23 |
Interest Coverage | — |
Quick Ratio
INKT
Profitability
Metric | INKT |
|---|---|
Return on Assets (Normalized) | −91.87% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
INKT
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|XlD#Sh | LOCK|tmRpP | $139B | |||
| Moderna Inc MRNA | LOCK|RDpY$$ | LOCK|PX? | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|<<?#zvL | LOCK|&&@V | $99B | |||
| argenx SE ADR ARGX | LOCK|!^@Z#@j | LOCK|pN | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|V@^#nd | LOCK|^c< | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|Sv@b?L$ | LOCK|Pr%F | $31B | |||
| Incyte Corp INCY | LOCK|vdfpPF | LOCK|#j | $25B | |||
| BioNTech SE ADR BNTX | LOCK|L%cw#vV | LOCK|%@$ | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|$&&b@@J | LOCK|N&@% | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|M^Y$jp? | LOCK|J@ | $16B |
United States